Skip to main content

Vor Biopharma Inc.

VOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001817229

In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $893.0M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Vor Biopharma Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of VOR: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders59160+2
Shares60.2M374.7K59.6M−235.2K (−0.4%)
Value$127.7M$794.4K$134.1M+$7.25M (+5.7%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (7)

Institutions that held Vor Biopharma Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to VOR in Q4 2023
InstitutionSharesValue% of portfolio
MAI Capital Management357,151$803.6K0.01%
Deutsche Bank AG31,835$71.6K0.00%
Jane Street Group, LLC16,945$38.1K0.00%
United Bank10,900$24.5K0.00%
Wexford Capital LP10,050$22.6K0.00%
Group One Trading, L.P.10,000$22.5K0.00%
Simplex Trading, LLC797$1.00K0.00%

Sold out (5)

Institutions that held Vor Biopharma Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of VOR in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Baker Bros. Advisors LP633,848$1.34M
Thrivent Financial for Lutherans149,690$317.0K
Squarepoint Ops LLC15,693$33.3K
Manufacturers Life Insurance Company, The10,221$21.7K
Gladius Capital Management LP10,009$21.2K

Not filed for Q4 2023 yet (1)

Institutions that held Vor Biopharma Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VOR in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
OUP Management Co., LLC374,714$794.4K